Physician profile
Rita A Abbud
NPI 1740256734
$2,552.47
in general payments reported to CMS, 2019-2025
17 companies · $12.42 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $342 · 2021: $240 · 2022: $581 · 2023: $346 · 2025: $12.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.75 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $733.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $394.53 | 2019-2023 | Dificid, Pifeltro, Lagevrio |
| Viiv Healthcare Company | $332.30 | 2019-2023 | Dovato |
| Janssen Biotech, INC. | $280.28 | 2019-2022 | |
| Janssen Products, Lp | $188.99 | 2021-2022 | |
| Melinta Therapeutics, LLC | $125.60 | 2019 | |
| Astellas Pharma US INC | $112.42 | 2019 | |
| Insmed, INC. | $87.20 | 2019-2022 | |
| Shionogi INC | $80.05 | 2021-2023 | Fetroja |
| Abbvie INC. | $62.20 | 2019-2023 | Teflaro |
| Ferring Pharmaceuticals INC. | $33.83 | 2023 | Rebyota |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Aimmune Therapeutics, INC. | $27.14 | 2023 | |
| Allergan, INC. | $20.05 | 2019 | |
| Nabriva Therapeutics, Plc | $20.00 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $13.42 | 2019 | |
| Sanofi Pasteur INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Abbud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.